Non Small Cell Lung Cancer
Conditions
Brief summary
Lung cancer is the leading cause of cancer related mortality. Among them, non small cell lung cancer accounts for 85%. Only part of patients could be treated with radical surgery. Mitochondria-targeted system therapy combined with radiofrequency ablation could be an alternative treatment. Small sample clinical cases verified that this therapy could be an efficacy and safe treatment in a short period. The primary aim of this trial is to determine if the efficacy of mitochondria-targeted system therapy combined with radiofrequency ablation is comparable to that of standard surgical interventions for patients with non-small cell lung cancer.
Interventions
OTHERMitochondria-targeted System Therapy Combined With Radiofrequency Ablation
Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites
PROCEDURESurgery
Patients will be treated with surgery
Sponsors
Shanghai 10th People's Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* The patient can understand and voluntarily join the study, sign the informed consent form, and the compliance is good. * Patients with single nodule. * Before IIB period according to the eighth edition of the TNM staging period. * No mediastinal lymph node metastasis. * No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments. * Eastern Cooperative Oncology Group performance status of 0 to 1 * Sufficient organ functions
Exclusion criteria
* Active bacterial or fungous infection. * Simultaneous or metachronous (within the past 5 years) double cancers. * Patients with contraindications to radiofrequency ablation and inability to complete treatment; * Women during pregnancy or breast-feeding. * Uncontrollable diabetes mellitus. * Patients with severe heart, lung, kidney disease or other systemic diseases who have been judged to have a severe impact on survival or who are pre-assessed to be unable to tolerate thoracoscopic surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival | From the date of randomization until the date of first documented progression，assessed up to 60 months |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | From the date of randomization until the date of death from any cause，assessed up to 60 months |
Countries
China
Contacts
Primary ContactLiH Fan, M.D.
Backup ContactMing Li, M.D.
Outcome results
None listed